噻唑烷二酮类药物对糖尿病患者哮喘发作风险的队列研究

The cohort study of thiazolidinediones on the risk of asthma exacerbation among patients with diabetes

目的探讨糖尿病患者服用噻唑烷二酮类药物与哮喘发作之间的关系。方法将428例糖尿病患者根据是否使用噻唑烷二酮类药物分成噻唑烷二酮类药物组和非噻唑烷二酮类药物组,比较两组患者的临床资料,哮喘发作情况及类固醇激素的使用情况,并采用多变量模型分析糖尿病患者哮喘发作风险因素。结果非噻唑烷二酮类药物组患者的平均年龄、伴有房颤及冠心病比例均明显高于噻唑烷二酮类药物组;非噻唑烷二酮类药物组患者哮喘发生率及类固醇激素药物使用率均明显高于噻唑烷二酮类药物组患者(P<0.05);多因素Logistic回归分析显示病程和是否使用噻唑烷二酮类药物与糖尿病患者的哮喘发作有密切关联。结论噻唑烷二酮类药物能够降低糖尿病患者的哮喘发作风险。

Objective To investigate the relationship between thiazolidinediones （TZDs） and the risk of asthma exacerbation among patients with diabetes, Methods According to the condition of whether took the TZDs or not,428 cases of diabetic patients were divided into the TZDs group and the non-TZDs group; then the clinical data, asthma attacks and steroid usage of patients in the two groups were compared,and the risk of asthma exacerbation among patients with diabetes was analyzed by multivariate model. Results The mean age,the proportion of the patients combined with atrial fibrillation and coronary heart disease of the non-TZDs group were significantly higher than that of the TZDs group（P〈0.05） ;the asthma exacerbation and steroid use of the patients in non-TZDs group were significantly higher than the TZDs group（P〈0.05） ; Multivariate Logistic regression analysis showed that duration and the condition of whether took the TZDs were closely correlated with the asthma exacerbation. Conclusion TZDs can reduce the risk of asthma in diabetes patients.